首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷分子呈像/呈影劑

市場調查報告書

商品編碼

1562474

比較顯影劑市場規模、佔有率、成長分析，按類型、形式、方式、途徑途徑、地區 - 產業預測，2024-2031 年

Contrast Media Market Size, Share, Growth Analysis, By Type, By Form, By Modality, By Route of Administration, By Region - Industry Forecast 2024-2031

出版日期: 2024年09月13日 | 出版商:

SkyQuest | 英文 260 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球顯影劑市場規模將為61億美元，從2023年的65.5億美元成長到2031年的116億美元，在預測期內（2024-2031年）預計複合年成長率為7.4%。

複雜合併症和慢性疾病的增加擴大了超音波、X 光、MRI 和電腦斷層掃描等診斷影像的使用。例如，美國FDA 於 2019 年 11 月核准了GE Healthcare 的大環 MRI顯影劑Clariscan。這些創新對於確定手術全期掃描和介入的需求至關重要，並有助於市場擴張。根據國家衛生委員會的數據，2019 年約有 8,100 萬美國患有多種慢性病，凸顯了這些疾病的顯著盛行率。據預測，在不久的將來，大約有1.57億美國將受到慢性病的影響。慢性病在老年人中尤其普遍：根據國家老化委員會的數據，大約 80% 的 65 歲以上的人至少患有一種慢性病，近 70% 的醫療保險受益人患有多種慢性病。到 2034 年，預計將有約 7,700 萬美國人年滿 65 歲或以上。此外，心臟衰竭作為美國的首要死因，正變得越來越普遍。美國心臟協會的報告稱，2019年約有65.9萬名美國死於心血管疾病，預計2031年心臟病患者數量將增加46%。預計這些趨勢將在預測期內推動全球市場對顯影劑的需求。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

GE Healthcare（US）
Bracco Imaging SpA（Italy）
Bayer AG（Germany）
Guerbet（France）
Lantheus Medical Imaging（US）
Unijules Life Sciences Ltd.（India）
JB Chemicals & Pharmaceuticals Limited（India）
Taejoon Pharm Co., Ltd.（South Korea）
Jodas Expoim（India）
Imax Diagnostic Imaging Limited（Ireland）
Yangtze River Pharmaceutical Group（China）
Livealth Biopharma（India）
Beijing Beilu Pharmaceutical Co., Ltd.（China）
Unispire Biopharma Private Limited（India）
Arco Lifesciences（I）Pvt. Ltd.（India）
Stanex Drugs & Chemicals Pvt. Ltd.（India）
Rege Imaging & Cine Films Private Limited（India）
K Diam Exim（India）
Onko Ilac San. ve Tic. AS（Turkey）
Fresenius Kabi（Germany）
Biem Ilac San. ve Tic. AS（Turkey）
Advacare Pharma（US）

簡介目錄

Product Code: SQMIG35B2070

Global Contrast Media Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.55 billion in 2023 to USD 11.60 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2024-2031).

The increasing prevalence of complex comorbidities and chronic illnesses is driving the growing use of diagnostic imaging procedures, including ultrasound, X-rays, MRI, and CT scans. For instance, the U.S. FDA approved GE Healthcare's Clariscan, a macrocyclic MRI contrast agent, in November 2019. Such innovations are crucial for determining the need for perioperative scans and interventions, contributing to market expansion. According to the National Health Council, approximately 81 million Americans had multiple chronic conditions in 2019, highlighting the significant prevalence of these diseases. Projections suggest that nearly 157 million Americans will be affected by chronic illnesses in the near future. Chronic diseases are particularly prevalent among older adults, with about 80% of individuals aged 65 and older having at least one chronic illness, and nearly 70% of Medicare recipients managing multiple conditions, according to the National Council on Aging. By 2034, it is anticipated that approximately 77 million Americans will be 65 or older. Additionally, heart failure, a major cause of death in the U.S., is becoming increasingly common. The American Heart Association reports that around 659,000 Americans died from cardiovascular disorders in 2019, and the number of heart disease cases is expected to rise by 46% by 2031. These trends are expected to drive the demand for contrast media in the global market over the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contrast Media market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contrast Media Market Segmental Analysis

Global Contrast Media Market is segmented by Type, Form, Modality, Route of Administration, Indication, Application, End User, and region. Based on Type, the market is segmented into Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media. Based on Form, the market is segmented into Liquid Contrast Media, Powder Contrast Media, and Other Forms. Based on Modality, the market is segmented into X-RAY, CT, MRI, and Ultrasound. Based on Route of Administration, the market is segmented into Intravascular Route [Intravenous (IV) route, Intra-arterial (IA) route], Oral Route, Rectal Route, and Other Routes. Based on Indication, the market is segmented into Cardiovascular Disease, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders, Neurological Disorders, and Nephrological Disorders. Based on Application, the market is segmented into Radiology, Interventional Radiology, and Interventional Cardiology. Based on End User, the market is segmented into Hospitals, Clinics, And Ambulatory Surgery Centers, and Diagnostic Imaging Centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Contrast Media Market

The global rise in chronic illnesses has led to a substantial increase in the demand for diagnostic imaging procedures and, by extension, contrast media. To address this growing need and to gain approval for new indications, manufacturers of contrast media have been heavily investing in research and development. This investment aims to bring innovative products to the market and enhance their existing offerings. For example, the US FDA approved a new 20-vial pack design of the ultrasound contrast agent Lumason for use by Bracco. This approval reflects the industry's efforts to meet the increasing demand for advanced imaging solutions and to provide healthcare professionals with more effective tools for diagnosing and managing chronic conditions.

Restraints in the Global Contrast Media Market

Contrast agents are widely utilized in various diagnostic techniques, such as MRI and CT scans, due to their ability to enhance imaging clarity. However, the market's growth may be somewhat limited by the potential for adverse effects and allergic reactions associated with their use. Although these negative reactions can vary from mild to severe, it is important to note that severe and major allergic responses are relatively rare.

Market Trends of the Global Contrast Media Market

Iodinated contrast medium is a type of intravenous radiocontrast used to enhance the visibility of vascular systems and organs during radiographic procedures. This contrast medium has been instrumental in detecting conditions such as cancer by improving imaging clarity. The current iodinated contrast media are developed from chemically modified tri-iodinated benzene rings. The effectiveness of iodinated contrast media in attenuating X-rays is influenced by the amount of iodine present in the tissue being imaged, with this attenuation being inversely related to the X-ray energy used. Consequently, the selection and quantity of contrast media needed for specific imaging tasks are based on the desired imaging quality.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Trade Analysis
Supply chain Analysis
Case study Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition

Contrast Media Market by Type

Market Overview
Iodinated Contrast Media
Gadolinium-based Contrast Media
Microbubble Contrast Media
Barium-based Contrast Media

Contrast Media Market by Form

Market Overview
Liquid Contrast Media
Powder Contrast Media
Other Forms

Contrast Media Market by Modality

Market Overview
X-RAY
CT
MRI
Ultrasound

Contrast Media Market by Route of Administration

Market Overview
Intravascular Route
- Intravenous (IV) route
- Intra-arterial (IA) route
Oral Route
Rectal Route
Other Routes

Contrast Media Market by Indication

Market Overview
Cardiovascular Disease
Cancer
Gastrointestinal Disorders
Musculoskeletal Disorders
Neurological Disorders
Nephrological Disorders

Contrast Media Market by Application

Market Overview
Radiology
Interventional Radiology
Interventional Cardiology

Contrast Media Market by End User

Market Overview
Hospitals, Clinics, And Ambulatory Surgery Centers
Diagnostic Imaging Centers

Contrast Media Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

GE Healthcare (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging SpA (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guerbet (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Medical Imaging (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Unijules Life Sciences Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
J.B. Chemicals & Pharmaceuticals Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Taejoon Pharm Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jodas Expoim (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Imax Diagnostic Imaging Limited (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yangtze River Pharmaceutical Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Livealth Biopharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Beilu Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Unispire Biopharma Private Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arco Lifesciences (I) Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stanex Drugs & Chemicals Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rege Imaging & Cine Films Private Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
K Diam Exim (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Onko Ilac San. ve Tic. A.S. (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biem Ilac San. ve Tic. A.S. (Turkey)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advacare Pharma (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments